SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 1,427.43 |
| Enterprise Value ($M) | 1,366.53 |
| Book Value ($M) | 731.70 |
| Book Value / Share | 8.04 |
| Price / Book | 1.95 |
| NCAV ($M) | -56.40 |
| NCAV / Share | -0.62 |
| Price / NCAV | -25.31 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.13 |
| Return on Assets (ROA) | -0.10 |
| Return on Equity (ROE) | -0.17 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.73 |
| Current Ratio | 1.90 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 293.20 |
| Assets | 1,081.30 |
| Liabilities | 349.60 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Increase Decrease Reduction Performance Obligation | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Glenview Capital Management, Llc | 1.39 | -76.13 | |
| 13G | Integrated Core Strategies (us) Llc | 5.00 | 1.13 | |
| 13G | Millennium Management Llc | 4.70 | ||
| 13G/A | Camber Capital Management LP | |||
| 13G/A | Vanguard Group Inc | 11.12 | 6.90 | |
| 13G/A | Wellington Management Group Llp | 8.07 | 6.37 | |
| 13G/A | State Street Corp | 5.25 | -6.37 | |
| 13G/A | BlackRock, Inc. | 16.60 | 2.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 128,494 | 642,193 | 20.01 | |
| 203,092 | 1,407,847 | 14.43 | |
| 233,837 | 988,819 | 23.65 | |
| 53,229 | 898,976 | 5.92 | |
| 53,441 | 530,879 | 10.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MRNA – Moderna, Inc. | MRSN – Mersana Therapeutics, Inc. |
| MRVI – Maravai LifeSciences Holdings, Inc. | NBIX – Neurocrine Biosciences, Inc. |
| NEOG – Neogen Corporation |
Financial data and stock pages provided by
Fintel.io